Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced presentations demonstrating the clinical impact of using its flagship metagenomic ...

The ability to generate presentations via Gemini is now rolling out for Gemini on the web. According to the tech giant, the rollout should be complete by November 12, 2025. It's w ...

Let's be honest: crafting a compelling presentation from a blank slate is a universal pain point. It's time-consuming, ...

The Ontario Public Service has the highest Microsoft Copilot use in the country, according to internal government documents, ...

Arima Genomics announced that it will present new data at the Association for Molecular Pathology (AMP) 2025 Annual Meeting.

Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher ScientificLOUISVILLE, Colo., ...

On October 29th, Acting Chief Judge Deshpande and Vice Chief Judge Kim discussed Director institution of AIA trials, where the Director will make ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today announces that it will be presenting brand-new data on ...

Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bionano Genomics Inc (BNGO-Q) from The Globe and Mail including charting and trades.

Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA ...